Tradestie Institutional Equity Comparison Engine
CNTA vs ZLAB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CNTA Overall Edge
CNTA Captures Institutional Edge (3โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Centessa Pharmaceuticals plc American Depositary Shares (CNTA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CNTA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ZLAB at N/M Forward P/E and -63.0% operating margin (-6.8% YoY). In options structure, CNTA sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against ZLAB sits in UNCLASSIFIED (58th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CNTA N/M vs ZLAB N/M Fwd P/E
Growth & Margin Winner
CNTA
Op Margin 0.0% vs -63.0% ยท YoY +0.0% vs -6.8%
Momentum & Technical Winner
CNTA
1Y +225.8% vs +9.7% ยท 52W Pos 100% vs 60%
Options & Structure Winner
CNTA
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (58th %ile IV)
CNTA
NASDAQ
Centessa Pharmaceuticals plc American Depositary Shares
Pharmaceutical Preparations
$40.50
+0.8% 1D
Market Cap
$6.2B
1M Return
+1.73%
1Y Return
+225.82%
Forward P/E
N/M
Unified AI Score
61.0 / 100
BUY
Tech 40.0
Fund 46.0
Flow 50.0
Mom 50.0
ZLAB
NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap
$3.0B
1M Return
+2.76%
1Y Return
+9.66%
Forward P/E
N/M
Unified AI Score
47.4 / 100
HOLD
Tech 25.0
Fund 39.0
Flow 50.0
Mom 53.5
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CNTA +225.82%
ZLAB +9.66%
Spread: +70.86 pp (CNTA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CNTA TTM Op. Margin: 0.0%
ZLAB TTM Op. Margin: -63.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNTA vs ZLAB. Trailing 12-month operating profitability (CNTA 0.0% vs ZLAB -63.0%) and valuation multiples (CNTA N/M vs ZLAB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CNTA | ZLAB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.2B | $3.0B | Larger Scale | CNTA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -6.8% | Higher Growth | CNTA |
| Operating Margin (TTM) Profitability | 0.0% | -63.0% | Higher Margin | CNTA |
| Net Profit Margin Profitability | 0.0% | -44.9% | Higher Margin | CNTA |
| Return on Equity (ROE) Capital Efficiency | -57.4% | -30.0% | Higher ROE | ZLAB |
| 52-Week Range Position Momentum | 100% ($12โ$41) | 60% ($16โ$29) | Stronger Trend | CNTA |
| Beta / 30D Volatility Risk Regime | 1.31ฮฒ ยท 4% Vol | 1.19ฮฒ ยท 78% Vol | Lower Realized Risk | CNTA |
| Unified Institutional Score Composite Signal | 61.0 / 100 (BUY) | 47.4 / 100 (HOLD) | Higher Composite | CNTA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CNTA vs ZLAB Buy Guide
CNTA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
ZLAB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
58th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CNTA nor ZLAB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.